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Introduction: Iron deﬁciency in congestive heart failure (CHF), with or without concomi-
tant  anaemia, is associated with health-related quality of life, NYHA functional class, and
exercise capacity. Prospective, randomised studies have demonstrated that correcting iron
deﬁciency improves the quality of life and functional status of patients with CHF, including
those who do not have anaemia.
Objective: The aim of this study was to analyse how frequently these iron parameters are
tested and thus determine the extent to which this quality improvement tool has been
implemented in patients admitted with CHF.
Methods: Retrospective observational study of patients from a university hospital diagnosed
with  CHF on admission between 01/01/2012 and 11/06/2013.
Results: Iron parameters were tested in 39% (324) of the 824 patients analysed. There was no
signiﬁcant difference in age between the patients whose iron was tested and those whose
iron was not tested, but the difference in terms of gender was signiﬁcant (p = 0.007). Glomeru-
lar  ﬁltration rate and haemoglobin, were signiﬁcantly lower in the group of patients whose
iron was tested (p < 0.001). The proportion of patients with anaemia, renal failure or both
was signiﬁcantly higher in the group of patients who had iron tests (p < 0.001).
Of  the 324 patients whose iron parameters were tested, 164 (51%) had iron deﬁciency.There were no differences between patients with and without iron deﬁciency in terms of
age  or gender. The iron parameters in both groups, ferritin and transferrin saturation index
er among the patients with iron deﬁciency (p < 0.001). The glomerularwere signiﬁcantly lowﬁltration rate values were signiﬁcantly lower in patients with no iron deﬁciency (p < 0.001).
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Signiﬁcant differences were also observed between those with and without iron deﬁciency
in  the proportion of patients with renal failure (79 vs. 66%, respectively, p = 0.013), but not in
terms of haemoglobin concentration.
Conclusion: Congestive heart failure is very frequently associated with anaemia, iron deﬁ-
ciency and renal failure. Despite the fact that correcting iron deﬁciency is known to improve
symptoms, testing of iron parameters in patients admitted with CHF is not performed as
often  as it should be.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Estudio  de  la  deﬁciencia  de  hierro  en  pacientes  con  insuﬁciencia  cardiaca
congestiva:  una  práctica  clínica  que  precisa  mayor  atención
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Insuﬁciencia renal
Síndrome cardio-renal
r  e  s  u  m  e  n
Introducción: La deﬁciencia de hierro en la insuﬁciencia cardiaca crónica (ICC), con o sin
anaemia concomitante, se halla asociada a la calidad de vida relacionada con la salud, clase
funcional NYHA, y a la capacidad de realización de ejercicio. Estudios prospectivos aleator-
izados han demostrado que la corrección de la deﬁciencia de hierro mejora la calidad de vida
y  el estadio funcional de estos pacientes con ICC, incluidos aquellos que no presentaban
anaemia.
Objetivo: El objetivo de este estudio es analizar la frecuencia de determinaciones de estos
parámetros de hierro y, por consiguiente, conocer la implementación de esta herramienta
de  mejoría de la calidad en pacientes que ingresan por ICC.
Métodos: Estudio observacional retrospectivo sobre pacientes de un hospital universitario,
que  fueron diagnosticados al ingreso de ICC, entre el 1/1/2012 y el 11/6/2013.
Resultados: El número de pacientes analizados fue de 824, de los que a un 39% (324) les
fueron evaluados los parámetros de hierro. Entre los pacientes no evaluados y sí evaluados
de  hierro, no se observó diferencia signiﬁcativa en la edad, aunque sí en el género, (p = 0,007).
Los  valores del ﬁltrado glomerular y de hemoglobina fueron signiﬁcativamente inferiores
en  el grupo de pacientes analizados de hierro (p < 0,001). La proporción de pacientes con
anaemia, insuﬁciencia renal y de aquellos que presentaban conjuntamente ambas comor-
bilidades fue signiﬁcativamente superior en el grupo de pacientes analizados de hierro
(p  < 0,001).
Entre los 324 pacientes evaluados de parámetros férricos, 164 pacientes (51%) mostraban
deﬁciencia de hierro. Entre los no deﬁcientes y sí deﬁcientes en hierro, no se observaron
diferencias signiﬁcativas en edad, ni en género. Los parámetros férricos de ambos gru-
pos,  ferritina e índice de saturación de la transferrina fueron signiﬁcativamente inferiores
entre los deﬁcientes de hierro, (p < 0,001). Los valores de ﬁltrado glomerular fueron signi-
ﬁcativamente inferiores en aquellos que no mostraban deﬁciencia de hierro, (p < 0,001). Se
observaron igualmente diferencias signiﬁcativas en la proporción de pacientes con insuﬁ-
ciencia renal, entre no deﬁcientes y sí deﬁcientes de hierro, (79 vs. 66%; p = 0,013), aunque
no  en los valores de hemoglobina.
Conclusión: La ICC se asocia con alta frecuencia a anaemia, deﬁciencia de hierro e insuﬁcien-
cia  renal. El estudio de los parámetros férricos en los pacientes que ingresan con ICC, pese
a  que la corrección de la deﬁciencia de hierro se asocia a mejoría de la sintomatología, no
se  realiza con la frecuencia necesaria.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Congestive heart failure (CHF) is associated with marked dete-
rioration in health-related quality of life (HRQoL). Patientsby-nc-nd/4.0/).
report symptoms such as dyspnoea during exercise, limited
capacity for physical work, tiredness, susceptibility to develop
stress and reduced mental and cognitive performance.1,2 Its
prevalence is 1–2% in the general population, and may exceed
10% in individuals over 80 years of age.3
1 6;3  6
f
t
p
C
t
o
n
p
m
s
p
c
i
m
o
v
e
h
t
t
s
w
d
C
S
A
d
M
2
h
t
s
d
w
i
o
g
t
o
l
t
b
t
h
C
<
r
3
M
gn e f r o l o g i a. 2 0 
A common feature of CHF is iron deﬁciency, resulting
rom exhaustion of iron stores, a deﬁcient intestinal absorp-
ion of iron and reduced bioavailability.4,5 Various randomised
rospective studies have demonstrated that in patients with
HF and iron deﬁciency with or without anaemia, iron reple-
ion improves symptoms, physical performance and quality
f life.6 The FAIR-HF7 study shows the importance of diag-
osing and treating iron deﬁciency in patients with CHF. A
ost hoc of the FAIR-HF study found signiﬁcant improve-
ent in patients after iron therapy. The clinical beneﬁt was
imilar in anaemic and non-anaemic patients, in terms of
atients’ overall self-perception, NYHA class, HRQoL and exer-
ise capacity.8
It is widely known that anaemia is a common comorbid-
ty in patients with CHF9; it is an independent prognostic
arker of mortality, hospital admissions and poor quality
f life.10,11 Correction of anaemia to normal or near-normal
alues has been associated with an improvement in HRQoL,
xercise capacity and symptoms of CHF.5,6
Congestive Heart Failure and CKD may share the cause (e.g.
ypertension), comorbidities (e.g. malnutrition) and risk fac-
ors (e.g. advanced age). Therefore, it is not rare to observe
hese two diseases together in what is known as cardio-renal
yndrome.12–14 In addition, if both entities occur together
ith anaemia, it is known as cardio-renal anaemia syn-
rome which represents a major independent risk factor for
HF.15,16
tudy  design  and  objectives
 retrospective observational study conducted in 824 patients
iagnosed on admission with CHF at Hospital Universitario
arqués de Valdecilla in Santander (Spain) between 1 January
012 and 11 June 2013.
The primary objective of the study was to determine
ow many  of these CHF patients underwent laboratory
esting for iron status evaluation (ferritin and transferrin
aturation index [TSI]). The secondary objectives were to
etermine the percentage of patients with iron deﬁciency,
ith or without anaemia, and to quantify the degree of renal
mpairment.
The number of determinations of serum iron (ferritin
r TSI), and haemoglobin (Hb), as well as calculations of
lomerular ﬁltration rate (GFR). It should be kept in mind
hat a single patient corresponded to one hospitalisation with
ne or more  rehospitalisation; none of one, more  than one
aboratory determinations could be generated in each hospi-
alisation. Patients’ iron parameters were considered to have
een investigated when they had undergone one determina-
ion of ferritin or TSI. Additional determination during their
ospital stay, were not included in the analysis.
Concomitant comorbidities, degree of CHF and stability of
HF were not analysed.
Anaemia was deﬁned as Hb level <13 g/dl in men  and
12 g/dl in women. Iron deﬁciency was considered if fer-
itin levels <100 g/ml, or serum ferritin between 100 and
00 g/ml plus a TSI <20%. GFR was calcululated using the
DRD equation. Patients were divided according to GFR into
rades 3–5 and >60 ml/min/1.73 m2, as recommended by the(3):249–254 251
KDIGO guidelines. A GFR <60 ml/min/1.73 m2 was considered
to be kidney failure.
Statistical analysis was performed using the SPSS v. 15.0
programme (SPSS Inc., Chicago, United States). Quantita-
tive variables with a normal distribution were expressed as
mean ± standard deviation, and those without normal dis-
tribution were expressed as median and interquartile range.
Qualitative variables were expressed as relative frequencies.
Normality was conﬁrmed with the Kolmogorov–Smirnov test,
and homogeneity of variance was conﬁrmed with the Levene
test. Comparison of means between 2 groups was performed
depending on the variable’s distribution, with Student’s t test
for independent groups or its non-parametric equivalent (the
Mann–Whitney U test). Comparison between groups for quali-
tative variables was performed with the 2 test. A p value < 0.05
was considered to be statistically signiﬁcant.
Results
A total of 824 patients were analysed. Of them, 39% (324) were
evaluated for iron parameters. No signiﬁcant differences were
observed with respect to age (81.3 [73.5–86.7] vs 81.9 [75.8–86.7]
years), although signiﬁcant differences were observed with
respect to gender (57 vs 88% men; p = 0.007). Values of GFR
(57.3 [43.1–60.0] vs 46.1 [34.1–60] ml/min/1.73 m2) and Hb (12.4
[43.1–60.0] vs 10.8 [9.7–12.0] g/dl) were signiﬁcantly lower in the
group of patients tested for iron (p < 0.001). The percentage of
patients with anaemia (56 vs 81%), kidney failure (55 vs 73%)
or both comorbidities at the same time (35 vs 63%) was signiﬁ-
cantly greater in the group of patients tested for iron (p < 0.001)
(Table 1).
Among the 324 patients evaluated for iron parameters, 164
patients (51%) showed iron deﬁciency. No signiﬁcant differ-
ences were observed with respect to age or gender between
those without iron deﬁciency and those with iron deﬁciency.
Ferritin was evaluated in 291 patients (90%), 127 (44%) of whom
had a level <100 g/l. TSI was estimated in 254 patients (78%),
192 (76%) of whom had a level <20%. Iron parameters for
the two groups—ferritin (325 [172.0–632.0] vs 69.5 [35.5–100.5]
g/l) and TSI (18% [11.5–26.0] vs 11% [7.0–14.3])—showed sig-
niﬁcant differences (p < 0.001). GFR also reﬂected signiﬁcant
differences (42.0 [30.7–57.6] vs 51.7 [36.8–60] ml/min/1.73 m2;
p < 0.001), as did the percentage of patients with CKD (79 vs
66%; p = 0.013). By contrast, Hb did not reﬂect signiﬁcant dif-
ferences between the two groups (11.0 ± 1.9 vs 10.9 ± 1.6 g/dl)
(Table 2).
Discussion
This study showed that potential iron deﬁciency is only stud-
ied in 39% of patients who are admitted with CHF  to our centre,
meaning that opportunities for clinical improvement are lost
in many  patients. This requires a reconsideration of routine
clinical practice in patients with CHF.
In our study, the age structure of the population analysed
matched that reﬂected by the Spanish Statistical Ofﬁce (INE) in
its survey on hospital morbidity17. Thus, 1% of patients were
252  n e f r o l o g i a. 2 0 1 6;3 6(3):249–254
Table 1 – Comparison of parameters between patients not tested for iron and tested for iron.
N Not tested for iron N Tested for iron p
Age (years) 500 81.3 (73.5–86.7) 324 81.9 (75.8–86.7) NS
Gender (male) 283 57% 152 88% 0.007
GFR (ml/min/1.73 m2) 496 57.3 (43.1–60.0) 324 46.1 (34.1–60) <0.001
Hb (g/dl) 498 12.4 (11.1–13.5) 324 10.8 (9.7–12.0) <0.001
Anaemia 278 56% 263 81% <0.001
CKD 272 55% 235 73% <0.001
Cardio-renal anaemia syndrome 173 35% 204 63% <0.001
Values in parentheses are interquartile ranges.
Table 2 – Comparison of parameters between non-iron-deﬁcient and iron-deﬁcient patients.
N Non-iron-deﬁcient N  Iron-deﬁcient p
Age (years) 160 81.6 (76.7–85.2) 164 82.6 (74.8–88.3) NS
Gender (male) 81 51% 71 43% NS
Ferritin (g/l) 127 325 (172.0–632.0) 164 69.5 (35.5–100.5) <0.001
TSI (%) 115 18 (11.5–26.0) 139 11 (7.0–14.3) <0.001
GFR (ml/min/1.73 m2) 160 42.0 (30.7–57.6) 164 51.7 (36.8–60) <0.001
Hb (g/dl) 160 11.0 ± 1.9 164 10.9 ± 1.6 NS
Anaemia 126 79% 137 84% NS
CKD 126 79% 109 66% 0.013
Cardio-renal anaemia syndrome 108 68% 96 59% NS
Values in parentheses are interquartile ranges.45 years of age or less, and more  than 80% of the population
analysed was older than 75 year.
Regarding the prevalence of iron deﬁciency in CHF, method-
ological differences in the design of several study have yielded
to non uniform results ranging from 13.7%, observed by Hug
et al.18; to intermediate reports in the 36–43% range, like
those indicated by Range et al.20 and Macdougall et al.4; to
63%, in a study by Comín-Colet et al.19. In our work, iron
was only evaluated in 39% of the population, with a preva-
lence of iron deﬁciency of 51%, a ﬁgure greater than the mean
reﬂected in the studies. This may probably be explained by
the limited percentage of population analysed and the older
age.
The prevalence of anaemia in CHF has been found to be
between 4% and 50%,21,22 depending on the study population
and the cut-off values for Hb used to deﬁne the lower limit
of normal. In a systematic review and meta-analysis, Groen-
veld et al.23 noted a prevalence of 37%. Extreme prevalences
like those noted by Silverberg et al.24 (79%) have undoubtedly
been due to methodological differences in study design. In
our study, we  found an overall prevalence of 66% of anaemic
and in the subgroup of 324 patients whose potential iron
deﬁciency had been investigated the prevalence rose to 79%
among those who  did not have iron deﬁciency and 84%
in those who did have it. In general, our study reﬂected a
greater prevalence than the majority of the studies evaluated.
We believe that this may be mainly due to patients’ older
age.Regarding the prevalence of CKD in CHF, the studies ana-
lysed have established it in the 30–64% range.25–27 In our
study, the prevalence of CKD was 62% overall and 73% in thesubgroup of patients who were evaluated for iron (79% in those
without iron deﬁciency and 66% in those with iron deﬁciency).
These percentages were close to the upper end of or even
above the range reﬂected in the studies analysed. Once again,
the explanation for this result may be found in the patients’
older age.
The epidemiology of cardio-renal anaemia syndrome is
complicated, since it depends on the prevalence of each of
its components, which in turn depend to a large extent on the
deﬁnitions used and the severity of the disease in the popula-
tion studied. As a result, there has been considerable variation
among the published data: from 3% to 22%.28,29 Our results
indicated a prevalence of cardio-renal anaemia syndrome of
46% relative to the total population. In the subgroup evalu-
ated for iron parameters, the prevalence rose to 63% (68% in
those who did not have iron deﬁciency and 59% in those who
did). As mentioned, the methodological differences in study
design, including the age of the population, may account for
this difference in prevalence between our study and those
reviewed.
Weak aspects of our study were its observational nature,
the fact that CHF was diagnosed by assigned physicians with-
out uniform criteria, the fact that it did not analyse reason for
admission or degree of CHF decompensation and the fact that
it did not include treatments for or analysis of causes of iron
deﬁciency. However, it should be noted that the data that we
have presented concerned a single centre, although this does
not mean that other centres act differently. The uniformity of
the data, as they came from a single centre, and the result-
ing uniformity of the analytical techniques, must be noted as
study strengths.
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We  believe that the results shown may represent a clear
rea of improvement for the treatment of heart failure.
onclusions
ron deﬁciency, with or without concomitant anaemia, was
ound to be signiﬁcantly associated with HRQoL, NYHA func-
ional class and exercise capacity. Bearing in mind the data
rom prospective studies that have demonstrated clinical
mprovement with the administration of iron in patients with
ron deﬁciency, early detection should be given more  substan-
ial consideration as a therapeutic target in the treatment of
HF. Our results have merely aimed to show that gap in rou-
ine medical practice, with limited laboratory determinations
f iron levels in patients with CHF.
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